Adage Capital Partners
WST icon

Adage Capital Partners’s West Pharmaceutical WST Stock Holding History

Adage Capital Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2M Sell
59,007
-5,200
-8% -$1.59M 0.03% 484
2026
Q1 		$16.1M Sell
64,207
-700
-1% -$174K 0.02% 557
2025
Q4 		$17.9M Buy
64,907
+9,400
+17% +$2.57M 0.03% 529
2025
Q3 		$14.6M Sell
55,507
-10,300
-16% -$2.5M 0.02% 556
2025
Q2 		$14.4M Sell
65,807
-145,300
-69% -$31.1M 0.02% 528
2025
Q1 		$47.3M Sell
211,107
-31,600
-13% -$8.71M 0.09% 237
2024
Q4 		$79.5M Buy
242,707
+64,300
+36% +$20.2M 0.14% 142
2024
Q3 		$53.6M Buy
178,407
+8,500
+5% +$2.6M 0.09% 221
2024
Q2 		$56M Sell
169,907
-27,700
-14% -$9.79M 0.1% 200
2024
Q1 		$78.2M Buy
197,607
+125,700
+175% +$46.5M 0.15% 142
2023
Q4 		$25.3M Sell
71,907
-1,500
-2% -$531K 0.05% 356
2023
Q3 		$27.5M Sell
73,407
-600
-0.8% -$232K 0.06% 311
2023
Q2 		$28.3M Sell
74,007
-75,100
-50% -$26.8M 0.06% 320
2023
Q1 		$51.7M Buy
149,107
+73,800
+98% +$21.6M 0.12% 207
2022
Q4 		$17.7M Sell
75,307
-100
-0.1% -$23.7K 0.04% 475
2022
Q3 		$18.6M Sell
75,407
-1,700
-2% -$518K 0.05% 428
2022
Q2 		$23.3M Sell
77,107
-200
-0.3% -$65.1K 0.05% 381
2022
Q1 		$31.8M Sell
77,307
-1,600
-2% -$626K 0.06% 325
2021
Q4 		$37M Sell
78,907
-500
-0.6% -$215K 0.07% 300
2021
Q3 		$33.7M Sell
79,407
-1,100
-1% -$464K 0.07% 299
2021
Q2 		$28.9M Buy
80,507
+24,700
+44% +$8.16M 0.06% 348
2021
Q1 		$15.7M Sell
55,807
-1,500
-3% -$429K 0.03% 536
2020
Q4 		$16.2M Sell
57,307
-25,250
-31% -$7.09M 0.04% 471
2020
Q3 		$22.7M Sell
82,557
-2,700
-3% -$715K 0.06% 343
2020
Q2 		$19.4M Buy
+85,257
New +$16.8M 0.05% 389
2019
Q1 		– Sell
-130,000
Closed -$12.7M – 743
2018
Q4 		$12.7M Sell
130,000
-20,000
-13% -$2.17M 0.04% 450
2018
Q3 		$18.5M Buy
+150,000
New +$16.8M 0.04% 417

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners's WST Position: Q2 2026 in Review

Adage Capital Partners reduced its West Pharmaceutical (WST) stake by 8.1% in Q2 2026, selling an estimated $1.59M and leaving 59,007 shares worth $21.2M. The position accounts for 0.03% of the portfolio, ranked #484.

Adage Capital Partners first reported a position in WST in Q3 2018 and has held it in 27 quarters since. The position peaked at $79.5M in Q4 2024. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Adage Capital Partners held 59,007 shares of West Pharmaceutical worth $21.2M as of Q2 2026.
  • Adage Capital Partners sold 5,200 West Pharmaceutical shares in Q2 2026, an estimated $1.59M.
  • West Pharmaceutical made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #484 holding.
  • Adage Capital Partners first reported a position in West Pharmaceutical in Q3 2018 and has held it in 27 quarters since.
  • Adage Capital Partners's West Pharmaceutical position peaked at $79.5M in Q4 2024.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.